Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

SHSE:600329 Stock Report

Market Cap: CN¥21.5b

Tianjin Pharmaceutical Da Ren Tang Group Balance Sheet Health

Financial Health criteria checks 5/6

Tianjin Pharmaceutical Da Ren Tang Group has a total shareholder equity of CN¥6.5B and total debt of CN¥1.3B, which brings its debt-to-equity ratio to 19.8%. Its total assets and total liabilities are CN¥11.0B and CN¥4.5B respectively. Tianjin Pharmaceutical Da Ren Tang Group's EBIT is CN¥796.8M making its interest coverage ratio -3. It has cash and short-term investments of CN¥1.5B.

Key information

19.8%

Debt to equity ratio

CN¥1.28b

Debt

Interest coverage ratio-3x
CashCN¥1.50b
EquityCN¥6.45b
Total liabilitiesCN¥4.52b
Total assetsCN¥10.97b

Recent financial health updates

Recent updates

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Could Easily Take On More Debt

Dec 18
Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Could Easily Take On More Debt

Are Investors Undervaluing Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329) By 48%?

Oct 27
Are Investors Undervaluing Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329) By 48%?

Why Investors Shouldn't Be Surprised By Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) 36% Share Price Surge

Oct 08
Why Investors Shouldn't Be Surprised By Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) 36% Share Price Surge

Some Shareholders Feeling Restless Over Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) P/E Ratio

Jul 26
Some Shareholders Feeling Restless Over Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) P/E Ratio

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Jul 05
Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Fewer Investors Than Expected Jumping On Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329)

Apr 18
Fewer Investors Than Expected Jumping On Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329)

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Mar 18
Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Financial Position Analysis

Short Term Liabilities: 600329's short term assets (CN¥7.1B) exceed its short term liabilities (CN¥4.2B).

Long Term Liabilities: 600329's short term assets (CN¥7.1B) exceed its long term liabilities (CN¥323.7M).


Debt to Equity History and Analysis

Debt Level: 600329 has more cash than its total debt.

Reducing Debt: 600329's debt to equity ratio has increased from 1.5% to 19.8% over the past 5 years.

Debt Coverage: 600329's debt is well covered by operating cash flow (91.8%).

Interest Coverage: 600329 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 08:47
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yalei YanBohai Securities Co., Ltd.
Chengzhi ChenCGS International
Shanshan LiChina Merchants Securities Co. Ltd.